Attached files

file filename
EX-99.1 - EX-99.1 - XBiotech Inc.d911116dex991.htm

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): April 17, 2015

 

 

XBIOTECH INC.

(Exact name of Registrant as specified in its charter)

 

 

British Columbia, Canada

(State of Incorporation)

001-37347

(Commission File Number)

N/A

(I.R.S. Employer Identification No.)

 

8201 E Riverside Dr. Bldg 4, Ste 100

Austin, Texas

  78744
(Address of principal executive offices)   (Zip Code)

(512) 386-2930

(Registrant’s telephone number, including area code)

 

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 


Item 8.01 Other Events.

On April 17, 2015, XBiotech Inc. (the “Company”) closed its previously announced initial public offering. The Company sold 4,000,000 shares of its common stock at an initial public offering price of $19 per share for a total offering amount of $76 million, before underwriting discounts and commissions and other company expenses. A copy of the Company’s press release announcing the closing of the offering is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

99.1 Press Release of XBiotech Inc., issued April 17, 2015


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: April 20, 2015 XBIOTECH INC.
By:

/s/ John Simard

John Simard
President


EXHIBIT INDEX

 

Exhibit

Number

  

Description

99.1    Press Release, issued April 17, 2015